eligibility_summary
Eligibility: Adults (18+) with self-confirmed MS who can use a web-enabled device, read/respond in English, and are prescribed OMB or OCR SC, receiving their first injection (Day 0) and completing a survey on Days 1–7. Exclusions: prior participation in OMB/OCR randomized trials, prior treatment with OMB or OCR SC, or cognitive impairment that limits survey participation.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
MS-PEKOS is an observational study comparing patient experience and injection-related reactions after first subcutaneous doses of two B‑cell–depleting biologics: 1) Ofatumumab (Kesimpta) – a fully human anti‑CD20 IgG1 monoclonal antibody, binds a membrane‑proximal CD20 epitope and depletes B cells via complement‑dependent cytotoxicity (CDC), antibody‑dependent cellular cytotoxicity (ADCC), and apoptosis. 2) Ocrelizumab SC – a humanized anti‑CD20 IgG1 monoclonal antibody, depletes B cells mainly via ADCC and apoptosis (less CDC than ofatumumab). Targeted cells/pathways: CD20+ pre‑B to mature B cells (sparing stem cells and plasma cells), leading to reduced antigen presentation to T cells, diminished pro‑inflammatory cytokines (e.g., IL‑6, GM‑CSF), and modulation of humoral/antigen‑presentation pathways.